Your browser doesn't support javascript.
Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines-A Case Series.
Girbardt, Christian; Busch, Catharina; Al-Sheikh, Mayss; Gunzinger, Jeanne Martine; Invernizzi, Alessandro; Xhepa, Alba; Unterlauft, Jan Darius; Rehak, Matus.
  • Girbardt C; Department of Ophthalmology, University Hospital Leipzig Medical Center, 04103 Leipzig, Germany.
  • Busch C; Department of Ophthalmology, University Hospital Leipzig Medical Center, 04103 Leipzig, Germany.
  • Al-Sheikh M; Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Gunzinger JM; Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Invernizzi A; Eye Clinic, Department of Biomedical and Clinical Sciences "Luigi Sacco", Luigi Sacco Hospital, University of Milan, 20157 Milan, Italy.
  • Xhepa A; Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University of Sydney, Sydney, NSW 2000, Australia.
  • Unterlauft JD; Eye Clinic, Department of Biomedical and Clinical Sciences "Luigi Sacco", Luigi Sacco Hospital, University of Milan, 20157 Milan, Italy.
  • Rehak M; Department of Ophthalmology, University Hospital Leipzig Medical Center, 04103 Leipzig, Germany.
Vaccines (Basel) ; 9(11)2021 Nov 17.
Article in English | MEDLINE | ID: covidwho-1524225
ABSTRACT

BACKGROUND:

To describe cases of retinal vascular events shortly after administration of mRNA or adenoviral-vectored COVID-19 vaccines.

DESIGN:

Retrospective, multicenter case series.

METHODS:

Six cases of retinal vascular events shortly after receiving COVID-19 vaccines.

RESULTS:

A 38-year-old, otherwise healthy male patient presented with branch retinal arterial occlusion four days after receiving his second dose of SARS-CoV-2 vaccination with Comirnaty® (BioNTech®, Mainz, Germany; Pfizer®, New York City, NY, USA). An 81-year-old female patient developed visual symptoms twelve days after the second dose of SARS-CoV-2 vaccination with Comirnaty® and was diagnosed with a combined arterial and venous occlusion in her right eye. A 40-year-old male patient noticed blurry vision five days after his first dose of SARS-CoV-2 vaccination with Comirnaty® and was diagnosed with venous stasis retinopathy in his left eye. A 67-year-old male was diagnosed with non-arteritic anterior ischemic optic neuropathy in his right eye four days after receiving the first dose of Vaxzevria® (AstraZeneca®, Cambridge, UK). A 32-year-old man presented with a sudden onset of a scotoma two days after receiving the second dose of SARS-CoV-2 vaccination with Spikevax® (Moderna, Cambridge, UK) and was diagnosed with a circumscribed nerve fiber infarction. A 21-year-old female patient developed an acute bilateral acute macular neuroretinopathy three days after receiving the first dose of SARS-CoV2-vaccine Vaxzevria® (AstraZeneca®, Cambridge, UK).

CONCLUSION:

This case series describes six cases of retinal vascular events shortly after receiving mRNA or adenoviral-vectored COVID-19 vaccines. The short time span between received vaccination and occurrence of the observed retinal vascular events raises the question of a direct correlation. Our case series adds to further reports of possible side effects with potential serious post-immunization complications of COVID-19 vaccinations.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Observational study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9111349

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Observational study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9111349